Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

Pembrolizumab plus chemotherapy followed by maintenance pembrolizumab reduced the risk of death or disease progression in patients with mismatch repair proficient or deficient advanced endometrial cancer.

Patients with resistant or refractory ovarian cancer experience clinical benefits after receiving botensilimab plus balstilimab in the phase 1 C-800 study.

Toripalimab plus bevacizumab and platinum-based chemotherapy produces a “promising” response rate in those with metastatic cervical cancer, according to an expert from Peking Union Medical College.

Adavosertib does not appear to be well tolerated in patients with previously treated recurrent or persistent uterine serous carcinoma in the phase 2b ADAGIO trial.

The phase 3 RUBY trial of dostarlimab plus carboplatin and paclitaxel significantly improved progression-free survival in patients with dMMR/MSI-H or MMRp/MSS endometrial cancer.

Overall survival after 10 years appears to be comparable regardless of whether patients 65 years or older received irradiation following surgery for low-risk, hormone receptor–positive breast cancer.

Durvalumab plus tremelimumab and hypofractionated radiotherapy yields observable clinical benefits in patients with gynecologic cancers, according to an expert from The University of Texas MD Anderson Cancer Center.

Niraparib maintenance therapy for recurrent ovarian cancer does not yield a significant overall survival benefit in an updated analysis of the phase 3 ENGOT-OV16/NOVA study.

Patients with advanced endometrial cancer experience early responses to lenvatinib plus pembrolizumab in both patients who were mismatch repair proficient and all-comers.

The Carolina Frailty Index Score indicates that patients with ovarian cancer classified as frail are highly more likely to die than patients classified as robust.

In the SOLAR phase 1b trial, a clinical benefit was observed when patients with RAS-mutated ovarian or endometrial cancer were given olaparib plus selumetinib.

The lower extremity lymphedema screening questionnaire and gynecological cancer lymphedema questionnaire appear to demonstrate comparable utility in assessing lymphedema in patients with advanced endometrial cancer.

A post hoc analysis demonstrated that dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival among patients with newly diagnosed, advanced ovarian cancer.

Durvalumab plus tremelimumab in combination with neoadjuvant chemotherapy did not yield any major adverse effects in patients with newly diagnosed advanced ovarian cancer in the phase 2 KGOG3046 trial.

Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.

An expert panel highlights novel therapeutic approaches for newly diagnosed and relapsed multiple myeloma.

Findings from 2 clinical trials support the approval of acalabrutinib as a treatment for patients with mantle cell lymphoma in China.

Treatment with retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy is associated with low long-term morbidity.

Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.

Adding avelumab to carboplatin plus paclitaxel appears to elicit a progression-free survival advantage compared with chemotherapy alone in those with advanced or recurrent endometrial cancer.

Efficacy and safety findings from the phase 3 GLOW trial assessing zolbetuximab and CAPOX in CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were consistent with the phase 3 SPOTLIGHT trial, according to an expert from Weill Cornell Medical College

Javier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Patients with metastatic or recurrent locally advanced Merkel cell carcinoma can now receive treatment with retifanlimab-dlwr following its accelerated approval by the FDA.

Findings from a cohort of the Childhood Cancer Survivor Study identify a prediction model that may accurately identify childhood cancer survivors at varying risks of late kidney failure.